Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACG102 in Refractory Active Systemic Lupus Erythematosus
NCT07749430Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, open-label, single-arm trial of ACG102 in systemic lupus erythematosus (SLE). Primary endpoints: Incidence of dose-limiting toxicities at 21 days, Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 52 weeks and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ACG102
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07749430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749430.